← All trials
NCT04271202
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2020
- Primary completion
- Aug 31, 2021
- Completion date
- Mar 31, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 120
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Harvard UniversityLead sponsor
- Eli LillyCollaborator
- Harvard UniversityOverall official - principal investigator
- Harvard UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.